Authors: JAILLON P DUPUIS B DAHAN R BOTTINEAU G CARON J CAZOR JL CHAUVENET M CLEMENT JP ESCANDE D FAISANDIER Y FUNCKBRENTANO C KOLSKY H KOEN R LACROIX D LEENHARDT A LEHNER JP PROST JF SWYNGHEDAUW B VASSORT G WEISSENBURGER J WOHLHUTER C

Citation: P. Jaillon et al., DRUG-INDUCED TORSADE-DE-POINTES - PRECLIN ICAL AND CLINICAL-STUDIES FOR THE PREDICTION OF A POTENTIAL PROARRHYTHMIC ADVERSE DRUG REACTION, Therapie, 52(4), 1997, pp. 271-280

Authors: DAHAN R JAILLON P LEHNER JP CAZOR JL CLOARECBLANCHARD L DAHAN R DUCHIER J GUINOT P JAILLON P LEHNER JP LOEB F MACQUINMAVIER C PUECH A ROLAND E ROUVEIX B TEULEESPIE M THULLIEZ C VITOU P

Citation: R. Dahan et al., HOW TO PREDICT THE THERAPEUTIC DOSE RANGE TO BE TESTED IN PHASE-III CLINICAL-TRIALS, Therapie, 48(4), 1993, pp. 297-301

Authors: FLAMANT R SPRIET A CAULIN C DOYON F CAZOR JL JAILLON P

Citation: R. Flamant et al., IS IT POSSIBLE TO DECREASE THE NUMBER OF PEOPLE STUDIED BEFORE DRUG REGISTRATION, Therapie, 48(4), 1993, pp. 329-331